Impact of piperacillin resistance on the outcome of Pseudomonas ventilator-associated pneumonia

Intensive Care Medicine

Volumn 32, Issue 12, 2006, Pages 1970-1978

  Combes, Alain ^a   Luyt, Charles Edouard ^a   Fagon, Jean Yves ^b   Wolff, Michel ^c   Trouillet, Jean Louis ^a   Chastre, Jean ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

Antibiotic resistant bacteria; Artificial respiration; Multivariable models; Outcome assessment

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; IMIPENEM; NEOMYCIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN;

ACUTE DISEASE; ADULT; AGE; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; COMORBIDITY; COMPARATIVE STUDY; CONFOUNDING VARIABLE; DISEASE SEVERITY; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PSEUDOMONAS AERUGINOSA; RECURRENCE RISK; RECURRENT INFECTION; RELAPSE; SCORING SYSTEM; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SUPERINFECTION; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

AGED; ANTI-BACTERIAL AGENTS; BRONCHOSCOPY; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INTENSIVE CARE UNITS; LOGISTIC MODELS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PIPERACILLIN; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SEVERITY OF ILLNESS INDEX;

EID: 33751537755     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-006-0355-7     Document Type: Article

References (31)

1. Chastre J, Fagon JY (2002) Ventilator-associated pneumonia. Am J Respir Crit Care Med 165:867-903
2. Crouch-Brewer S, Wunderink RG, Jones CB, Leeper KV Jr. (1996) Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 109:1019-1029
3. Fagon JY, Chastre J, Domart Y, Trouillet JL, Gibert C (1996) Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis 23:538-542
4. National Nosocomial Infections Surveillance (NNIS) (2004) Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32:470-485
5. Carmeli Y, Troillet N, Karchmer AW, Samore MH (1999) Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 159:1127-1132
6. Cosgrove SE, Carmeli Y (2003) The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 36:1433-1437
7. Blot S, Vandewoude K, De Bacquer D, Colardyn F (2002) Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization. Clin Infect Dis 34:1600-1606
8. Blot S, Vandewoude K, Hoste E, Colardyn F (2003) Reappraisal of attributable mortality in critically ill patients with nosocomial bacteraemia involving Pseudomonas aeruginosa. J Hosp Infect 53:18-24
9. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y (2006) Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 50:43-48
10. Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, Kim EC, Choe KW (2003) Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 37:745-751
11. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW (2005) Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist 11:68-74
12. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH (2005) Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 49:1306-1311
13. Raymond DP, Pelletier SJ, Crabtree TD, Evans HL, Pruett TL, Sawyer RG (2003) Impact of antibiotic-resistant Gram-negative bacilli infections on outcome in hospitalized patients. Crit Care Med 31:1035-1041
14. Trouillet JL, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C (2002) Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 34:1047-1054
15. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S (2003) Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. J Am Med Assoc 290:2588-2598
16. McCabe WR, Jackson GG (1962) Gram-negative bacteremia. Arch Intern Med 110:847-864
17. Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. J Am Med Assoc 270:2957-2963
18. Vincent JL, Moreno R, Takala J, Willatts S, Mendonca A de, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707-710
19. Fagon JY, Chastre J, Novara A, Medioni P, Gibert C (1993) Characterization of intensive care unit patients using a model based on the presence or absence of organ dysfunctions and/or infection: the ODIN model. Intensive Care Med 19:137-144
20. Weinberg PF, Matthay MA, Webster RO, Roskos KV, Goldstein IM, Murray JF (1984) Biologically active products of complement and acute lung injury in patients with the sepsis syndrome. Am Rev Respir Dis 130:791-796
21. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R (1994) The American-European Consensus Conference on ARDS. definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149:818-824
22. Comite de l'Antibiogramme de la Societe Francaise de Microbiologie report (2003) Int J Antimicrob Agents 21:364-391
23. Katz MA (1999) Mutivariate analysis. Cambridge University Press, New York
24. Spanik S, Krupova I, Trupl J, Kunova A, Novotny J, Mateicka F, Pichnova E, Sulcova M, Sabo A, Jurga L, Krcmery Jr VV (1999) Bacteremia due to multiresistant Gram-negative bacilli in neutropenic cancer patients: a case-controlled study. J Infect Chemother 5:180-184
25. Sadikot RT, Blackwell TS, Christman JW, Prince AS (2005) Pathogenhost interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 171:1209-1223
26. Cao B, Wang H, Sun H, Zhu Y, Chen M (2004) Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect 57:112-118
27. Arruda EA, Marinho IS, Boulos M, Sinto SI, Caiaffa HH, Mendes CM, Oplustil CP, Sader H, Levy CE, Levin AS (1999) Nosocomial infections caused by multiresistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 20:620-623
28. Defez C, Fabbro-Peray P, Bouziges N, Gouby A, Mahamat A, Daures JP, Sotto A (2004) Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J Hosp Infect 57:209-216
29. Harris AD, Perencevich E, Roghmann MC, Morris G, Kaye KS, Johnson JA (2002) Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob Agents Chemother 46:854-858
30. Hsu DI, Okamoto MP, Murthy R, Wong-Beringer A (2005) Fluoroquinolone- resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. J Antimicrob Chemother 55:535-541
31. Shorr AF, Combes A, Kollef MH, Chastre J (2006) Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med 34:700-706